Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. The company’s primary mission is to deliver innovative medicines that leverage RNAi technology, a process that harnesses natural biological pathways to silence specific disease-causing genes. Alnylam’s portfolio includes therapies for rare genetic, cardio-metabolic, and hepatic diseases, addressing conditions with significant unmet medical needs. Notable products include AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) for transthyretin-mediated amyloidosis, as well as GIVLAARI (givosiran) and OXLUMO (lumasiran) for rare metabolic disorders. The company has achieved notable milestones, such as the approval of multiple first-in-class RNAi therapeutics, and maintains a strong presence globally, driven by sustained revenue growth and a robust research pipeline. With a focus on pioneering RNAi-based medicines, Alnylam Pharmaceuticals plays a critical role in advancing genetic medicine and transforming disease treatment paradigms for both rare and prevalent conditions.